Drug Profile

NTR 1011

Alternative Names: NTR-1011

Latest Information Update: 26 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neutrolis Therapeutics
Class Albumins; Anti-inflammatories; Antirheumatics; Deoxyribonucleases; Recombinant fusion proteins
Mechanism of Action Deoxyribonuclease I replacements; Extracellular trap inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

29 Oct 2025 NTR 1011 is available for licensing as of 29 Oct 2025. https://www.neutrolis.com/contact-us
29 Oct 2025 Neutrolis plans phase IIa trial for Systemic lupus erythematosus and Rheumatoid arthritis in 2026
04 Sep 2025 Phase-I clinical trials in Rheumatoid arthritis in USA (IV) (NCT07237659)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com